JP2000504211A - デプレニル誘導性タンパク質 - Google Patents
デプレニル誘導性タンパク質Info
- Publication number
- JP2000504211A JP2000504211A JP9524806A JP52480697A JP2000504211A JP 2000504211 A JP2000504211 A JP 2000504211A JP 9524806 A JP9524806 A JP 9524806A JP 52480697 A JP52480697 A JP 52480697A JP 2000504211 A JP2000504211 A JP 2000504211A
- Authority
- JP
- Japan
- Prior art keywords
- dip1
- cells
- dna
- activity
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
- C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
- C07D295/03—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to acyclic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/20—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic unsaturated carbon skeleton
- C07C211/23—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic unsaturated carbon skeleton the carbon skeleton containing carbon-to-carbon triple bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
- C07C211/27—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
- C07C211/31—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the six-membered aromatic ring being part of a condensed ring system formed by at least three rings
- C07C211/32—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the six-membered aromatic ring being part of a condensed ring system formed by at least three rings containing dibenzocycloheptane or dibenzocycloheptene ring systems or condensed derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/78—Ring systems having three or more relevant rings
- C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
- C07D311/82—Xanthenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
- C07D313/02—Seven-membered rings
- C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
- C07D313/10—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with two six-membered rings
- C07D313/14—[b,f]-condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
- C07C2603/30—Ortho- or ortho- and peri-condensed systems containing three rings containing seven-membered rings
- C07C2603/32—Dibenzocycloheptenes; Hydrogenated dibenzocycloheptenes
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.配列番号1に示す配列を有するデプレニル誘導性タンパク質1(DIP1) およびその機能性誘導体。 2.神経性疾患においてアポトーシス性細胞死の妨止または緩和のために使用す る請求項1に記載のタンパク質、その機能性誘導体またはDIP1活性のモジュ レーター。 3.神経細胞と化合物または化合物の組み合わせと接触させ、その上昇が当該化 合物または化合物の組み合わせの神経細胞をアポトーシスから救済する能力の指 標となるDIP1活性の強度を観察することを含む、化合物または化合物の組み 合わせを神経細胞をアポトーシスから救済する能力についてスクリーニングする 方法。 4.神経活性薬または神経活性薬の組み合わせのインビボの活性をモニターする 請求項3記載の方法。 5.神経細胞におけるDIP1活性を増大する効果を有する、神経細胞をアポト ーシスから救済するための組成物。 6.神経細胞においてDIP1の活性をモジュレートする効果がある組成物の薬 学的有効量を患者に投与すること含む神経疾状を有する患者の処置方法。 7.神経細胞に投与したとき、当該細胞におけるDIP1活性を増大させる効果 を有する化合物。 8.式I〜XXIIの化合物のうちの何れかを選択した請求項7記載の化合物。 9.DIP1の活性を増大させる組成物の製造における化合物の使用。 10.式I〜XXIIの化合物のうちの何れかの化合物を選択した請求項9記載の 使用。 11.請求項1記載のDIP1をコードする核酸。 12.機能制御エレメントを含む請求項11記載の核酸のフラグメント。 13.異種遺伝子の発現を制御するためのDIP1制御配列の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9600660.6A GB9600660D0 (en) | 1996-01-12 | 1996-01-12 | Protein |
GB9600660.6 | 1996-01-12 | ||
PCT/EP1996/005800 WO1997025421A2 (en) | 1996-01-12 | 1996-12-21 | PROTEIN INDUCED BY DEPRENYL$m(3) |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2000504211A true JP2000504211A (ja) | 2000-04-11 |
JP2000504211A5 JP2000504211A5 (ja) | 2004-11-11 |
Family
ID=10786972
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP9524806A Ceased JP2000504211A (ja) | 1996-01-12 | 1996-12-21 | デプレニル誘導性タンパク質 |
Country Status (8)
Country | Link |
---|---|
US (1) | US6232118B1 (ja) |
EP (1) | EP0873406B1 (ja) |
JP (1) | JP2000504211A (ja) |
AT (1) | ATE310083T1 (ja) |
AU (1) | AU1305097A (ja) |
DE (1) | DE69635457D1 (ja) |
GB (1) | GB9600660D0 (ja) |
WO (1) | WO1997025421A2 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000021513A2 (en) * | 1998-10-09 | 2000-04-20 | Shankar L Sai Latha | Methods for treating multiple sclerosis |
EP1621190A1 (en) * | 1998-10-09 | 2006-02-01 | L. Sai Latha Shankar | Deprenyl compounds for treating Multiple Sclerosis |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
US5646008A (en) * | 1993-06-22 | 1997-07-08 | The Regent Of The University Of Michigan | Vertebrate apoptosis gene: compositions and methods |
-
1996
- 1996-01-12 GB GBGB9600660.6A patent/GB9600660D0/en active Pending
- 1996-12-21 US US09/101,519 patent/US6232118B1/en not_active Expired - Lifetime
- 1996-12-21 DE DE69635457T patent/DE69635457D1/de not_active Expired - Fee Related
- 1996-12-21 WO PCT/EP1996/005800 patent/WO1997025421A2/en active IP Right Grant
- 1996-12-21 AT AT96944634T patent/ATE310083T1/de not_active IP Right Cessation
- 1996-12-21 EP EP96944634A patent/EP0873406B1/en not_active Expired - Lifetime
- 1996-12-21 AU AU13050/97A patent/AU1305097A/en not_active Abandoned
- 1996-12-21 JP JP9524806A patent/JP2000504211A/ja not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
GB9600660D0 (en) | 1996-03-13 |
AU1305097A (en) | 1997-08-01 |
WO1997025421A3 (en) | 1997-09-12 |
WO1997025421A2 (en) | 1997-07-17 |
ATE310083T1 (de) | 2005-12-15 |
EP0873406B1 (en) | 2005-11-16 |
EP0873406A2 (en) | 1998-10-28 |
US6232118B1 (en) | 2001-05-15 |
DE69635457D1 (de) | 2005-12-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100692333B1 (ko) | Tie 리간드 상동체 | |
WO2003101388A2 (en) | Human solute carrier family 7 member 11 (hslc7a11) | |
JP2003116587A (ja) | ポリペプチド及び同じものをコードしている核酸 | |
JP2004516227A (ja) | 免疫関連疾患を治療するための組成物と方法 | |
JP2005245469A (ja) | 腫瘍サプレッサ遺伝子、並びに癌の検出、腫瘍進行のモニタおよび癌処置のための方法 | |
JP2002543787A (ja) | 白血球免疫グロブリン様受容体(lir)と命名された免疫調節因子のファミリー | |
JP2002539773A (ja) | 分泌タンパク質およびそれらをコードする核酸 | |
JP3497133B2 (ja) | A−33関連抗原およびそれらの薬理学的使用 | |
JPH11514224A (ja) | 新規なヘモポエチン受容体およびそれをコードする遺伝子配列 | |
JP2002535979A (ja) | 新規rgs含有分子およびその使用 | |
JPH10511936A (ja) | ヒトソマトスタチン様受容体 | |
JP4314386B2 (ja) | Bcl−2調節因子(BMF)配列及びアポトーシスの調節におけるそれらの使用 | |
US20170164591A1 (en) | Sperm-Specific Cation Channel, Catsper2, and Uses Therefor | |
US6171857B1 (en) | Leucine zipper protein, KARP-1 and methods of regulating DNA dependent protein kinase activity | |
US7339029B2 (en) | Sperm-specific cation channel, CatSper2, and uses therefor | |
US6586581B1 (en) | Prolactin regulatory element binding protein and uses thereof | |
JP2000504211A (ja) | デプレニル誘導性タンパク質 | |
KR20030045083A (ko) | β-카테닌 핵 국재화 단백질 | |
EP0727486A2 (en) | Tumour suppressor gene | |
JP2003524600A (ja) | 免疫関連疾患治療のための組成物及び方法 | |
WO2001046415A1 (fr) | Polypeptides de type tachykinine et utilisation associee | |
WO2004069869A1 (ja) | アポトーシス誘導遺伝子およびその利用 | |
JP2002508666A (ja) | 神経幹細胞遺伝子 | |
US20040091960A1 (en) | Novel physiologically active peptides and use thereof | |
JP2001513755A (ja) | 癌を検出するためのヒスチジン・デカルボキシラーゼのアッセイ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20031216 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20031216 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060815 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20070115 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20070213 |